awmsg logo



azithromycin (Zedbac®)


Reference No. 2476

Publication date:
14/08/2014


Appraisal information

azithromycin (Zedbac®) 500 mg powder for solution for infusion


Company: Aspire Pharma Ltd
BNF category: Infections
NMG meeting date: 18/06/2014
AWMSG meeting date: 16/07/2014
   
   
Submission Type: Limited Submission
Status: Recommended with restrictions
Advice No: 1914
Ministerial ratification: 13/08/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Azithromycin (Zedbac®) 500 mg powder for solution for infusion is recommended as an option for restricted use within NHS Wales. Azithromycin (Zedbac®) 500 mg powder for solution for infusion should be restricted for use within NHS Wales for the treatment of community-acquired pneumonia (CAP) due to susceptible microorganisms, in adult patients where initial intravenous therapy is required. Azithromycin (Zedbac®) 500 mg powder for solution for infusion is not recommended for use within NHS Wales for the treatment of pelvic inflammatory disease (PID) due to susceptible microorganisms, in patients where initial intravenous therapy is required.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download